Vamil Divan

Johnson & Johnson (NYSE:JNJ) reported its first-quarter results ahead of expectations, with the beat driven by higher sales from its Innovative Medicine segment. • Johnson & Johnson stock is trending lower. Why is JNJ stock trading lower? The latest results "set the stage for...

Shares of Johnson & Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report. Here are some key analyst takeaways. BofA Securities analyst Tim Anderson reiterated a Neutral rating, while raising the price target from $161 to $175. Guggenheim Securities...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...

Eli Lilly And Co (NYSE: LLY) received an upgrade from a Mizuho Securities analyst ahead of a key data readout in March. The Lilly Analyst: Vamil Divan upgraded Lilly shares from Neutral to Buy and increased the price target from $164 to $222. The Lilly Thesis: Lilly has navigated through a...

Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported disappointing fourth-quarter earnings Wednesday before the market open, sending its shares down about 8 percent. The Analyst Credit Suisse analyst Vamil Divan maintained a Market Perform rating and lowered the price target for Teva shares...

FDA approval of Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA)'s migraine preventive medication Ajovy led Credit Suisse to raise its price target for the stock Monday.  The Analyst Credit Suisse analyst Vamil Divan maintained a Neutral rating on the shares of Teva and...

Portola Pharmaceuticals Inc (NASDAQ: PTLA), a biotech focusing on thrombosis, other hematological disorders and inflammation, received a one-notch upgrade from Credit Suisse.  The Analyst Analyst Vamil Divan upgraded Portola from Underperform to Neutral and raised the price target from $...

AbbVie Inc (NYSE: ABBV)'s stock is up 51 percent year-over-year, but its lifeblood may be draining. The Rating Credit Suisse analysts Vamil Divan and Michael Morabito downgraded AbbVie to Underperform and lowered their price target from $104 to $89. The Thesis The analysts attribute AbbVie...

Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares reclaimed the $40 level for the first time since February after a positive FDA decision on a drug meant to reverse anticoagulation brought about by drugs such as Bayer AG (ADR) (OTC: BAYRY)'s rivaroxaban, and apixaban jointly developed by...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced a restructuring program late last year that is now showing some signs of early success, according to Credit Suisse. The Analyst Credit Suisse's Vamil Divan upgraded Teva's stock rating from Neutral to Outperform with a...

Analysts at Credit Suisse downgraded Eli Lilly and Co (NYSE: LLY) in October and just three months later, the firm believes another downgrade is warranted. The Analyst Credit Suisse's Vamil Divan downgraded Eli Lilly's stock from Neutral to Underperform with a price target lowered...

Impressed with the turnaround initiatives at Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), an analyst at Credit Suisse upgraded the company's shares. The Analyst Credit Suisse analyst Vamil Divan upgraded shares of Teva from Underperform to Neutral and increased the price...

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) has a lot cooking and its spread appeals to the Street's appetite. The pharma firm caught a Buy rating Monday to compound three existing Buys and two Holds — each of which correspond with price targets that assume an upside for the stock....

Credit Suisse in a note Monday listed seven catalysts for Eli Lilly and Co (NYSE: LLY) shares over the coming year even as it downgraded the shares of the company on the pretext that there are limited drivers of further upside after the stock's recent run, which lifted it by 13 percent since mid-...